It is thus highly probable that the lower platelet aggregation reported by Sakamoto in losartan-treated patients relies on the beneficial effect of losartan on hypertension and risk factors of thrombosis such as evidenced by the decline in tissue factor and PAI-1. Here, SERPINE1 is linked to Hypertension.